Latest Information Update: 12 Dec 2006
At a glance
- Originator Nonindustrial source; Pierre Fabre
- Developer Pierre Fabre
- Class Antineoplastics
- Mechanism of Action Growth hormone releasing factor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Apr 1997 No-Development-Reported for Cancer in France (Unknown route)
- 20 Jul 1995 Preclinical development for Cancer in France (Unknown route)